Protagonist Therapeutics (PTGX) Receivables - Net (2015 - 2021)

Protagonist Therapeutics has disclosed Receivables - Net across 7 years of filings, most recently posting $100000.0 for Q1 2021.

• Receivables - Net for Q1 2021 came in at $100000.0, down 66.67% year-over-year; the trailing twelve-month figure through Mar 2021 was $100000.0 (down 66.67% YoY), and the FY2019 annual result was $300000.0, down 2.91% from the prior year.
• Receivables - Net came in at $100000.0 for Q1 2021 at Protagonist Therapeutics, roughly flat from $100000.0 in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $700000.0 in Q3 2019 to a low of $19000.0 in Q2 2017.
• The 5-year median for Receivables - Net is $103000.0 (2017), against an average of $199266.7.
• Across the five-year window, Receivables - Net slumped 91.52% in 2017 and soared 459.38% in 2019, its largest moves.
• Protagonist Therapeutics' Receivables - Net stood at $58000.0 in 2017, then jumped by 432.76% to $309000.0 in 2018, then slipped by 2.91% to $300000.0 in 2019, then slumped by 66.67% to $100000.0 in 2020, then changed by 0.0% to $100000.0 in 2021.
• The last three Receivables - Net figures came in at $100000.0 (Q1 2021), $100000.0 (Q2 2020), and $300000.0 (Q1 2020), per Business Quant data.